Experts discuss real-world evidence and research gaps in metastatic castration-sensitive prostate cancer

Industry and academic experts gathered to examine how real-world evidence can be used to compare treatments for metastatic castration-sensitive prostate cancer. They highlighted the strengths and limitations of clinical trial data, noting that trials often enroll selective patient populations that may not reflect everyday practice.

The discussion also addressed sources of bias that can arise in observational studies, such as confounding factors and data quality issues. Participants emphasized the need for rigorous methodological standards to ensure that real-world findings reliably inform treatment decisions.

Finally, the panel identified several priority areas for future research, including head‑to‑head comparisons of emerging therapies, long‑term safety monitoring, and the integration of biomarker data to personalize care pathways.